The Chronic Lymphocytic Leukemia Channel on VJHemOnc is an independent medical education platform, supported with funding from AstraZeneca (Diamond), AbbVie (Platinum), BeOne Medicines (Silver) and Lilly (Silver). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
ASH 2020 | Extended follow-up of the TRANSCEND-CLL-004 monotherapy cohort
Tanya Siddiqi, MD, City of Hope National Medical Center, Duarte, CA, gives an update on the Phase I monotherapy cohort of the TRANSCEND-CLL-004 study (NCT03331198), investigating lisocabtagene maraleucel (liso-cel) as a treatment for relapsed/refractory chronic lymphocytic leukemia (CLL) and small lymphocytic lymphoma (SLL). The follow-up study reported that liso-cel induced durable responses in many patients. At 18-months follow-up, the median duration of response had not been reached. High rates of undetectable measurable residual disease were observed, indicating deep remission in these patients. Liso-cel was still detectable in treated patients for up to 18 months post-infusion and no late or delayed adverse effects of concern emerged. This interview took place during the 62nd American Society of Hematology (ASH) Annual Meeting and Exposition, 2020.
